Purple Biotech (PPBT) Share-based Compensation (2014 - 2026)
Purple Biotech's (PPBT) quarterly Share-based Compensation came in at $67000.0 in Q2 2026, up 13.56% year-over-year from $59000.0 in Q2 2025, and down 27.96% quarter-over-quarter from $93000.0 in Q1 2026.
Powered by 
Analysis
Purple Biotech (PPBT) Share-based Compensation (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Share-based Compensation for 12 consecutive years, with $67000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Share-based Compensation rose 13.56% year-over-year to $67000.0 in Q2 2026; TTM through Jun 2026 was $317000.0, a 26.8% increase from a year earlier, with the FY2025 full-year figure at $309000.0, down 46.91% from the prior year.
- Share-based Compensation was $67000.0 for Q2 2026 at Purple Biotech, down from $93000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $839000.0 in Q4 2022 and troughed at -$43000.0 in Q4 2025.
- A 5-year average of $296555.6 and a median of $209000.0 in 2024 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation surged 143.37% in 2023 and sank 118.78% in 2024, its largest moves.
- Over 5 years, Share-based Compensation stood at $839000.0 in 2022, then slumped by 78.43% to $181000.0 in 2023, then sank by 118.78% to -$34000.0 in 2024, then fell by 26.47% to -$43000.0 in 2025, then jumped by 255.81% to $67000.0 in 2026.
- The last three Share-based Compensation figures came in at $67000.0 (Q2 2026), $93000.0 (Q1 2026), and -$43000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.24 Bn | 192.25 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 180.01 Bn | 176.83 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.33 Bn | 123.47 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.87 Bn | 73.87 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.27 Bn | 55.08 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.93 Bn | 48.79 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.17 Bn | 29.86 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.89 Bn | 30.60 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.12 Bn | 29.12 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Purple Biotech | 282,022.44 | 282,022.44 | - | 67,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 67,000.00 |
| Mar 31, 2026 | 93,000.00 |
| Dec 31, 2025 | -43,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Dec 31, 2024 | -34,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Jun 30, 2024 | 218,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Dec 31, 2023 | 181,000.00 |
| Sep 30, 2023 | 449,000.00 |
| Jun 30, 2023 | 493,000.00 |
| Mar 31, 2023 | 752,000.00 |
| Dec 31, 2022 | 839,000.00 |
| Sep 30, 2022 | 707,000.00 |
| Jun 30, 2022 | 557,000.00 |
| Mar 31, 2022 | 309,000.00 |
| Dec 31, 2021 | 697,000.00 |
| Sep 30, 2021 | 392,000.00 |